Tourmaline Bio Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	13	13.04	2.18	13.26	7.41	5.01
Research & Development	30.33	32.37	17.53	34.25	15.28	13.37
Other Operating Expenses	-4.48	0	0	0	0	0
Operating Expenses	38.85	45.41	19.7	47.51	22.68	18.38
Operating Income	-38.85	-45.41	-19.7	-47.51	-22.68	-18.38
Other Expense / Income	-5.91	-3.29	-	0.33	0.02	-0.22
Pretax Income	-32.94	-42.12	-19.7	-47.83	-22.71	-18.16
Net Income	-32.94	-42.12	-19.7	-47.83	-22.71	-18.16
Shares Outstanding (Basic)	24	5	1	3	1	1
Shares Outstanding (Diluted)	24	5	1	3	1	1
Shares Change	2558.06%	441.28%	-69.89%	335.69%	4.73%	-
EPS (Basic)	-4.08	-8.87	-22.46	-16.40	-34.00	-28.40
EPS (Diluted)	-4.08	-8.87	-22.46	-16.40	-34.00	-28.40
Free Cash Flow	-25.84	-28.14	-6.53	-42.43	-20.5	-18.22
Free Cash Flow Per Share	-1.07	-5.93	-7.44	-14.57	-30.66	-28.55
Dividend Per Share	1.512	1.512	-	-	-	-
EBITDA	-33.37	-41.97	-19.68	-47.21	-22.26	-17.78
Depreciation & Amortization	-0.44	0.16	0.02	0.62	0.45	0.38
EBIT	-32.94	-42.12	-19.7	-47.83	-22.71	-18.16

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).